Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from BioNow

23:56 EDT 22nd September 2017 | BioPortfolio

Here are the most relevant search results for "BioNow" found in our extensive news archives from over 250 global news sources.

More Information about BioNow on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioNow for you to read. Along with our medical data and news we also list BioNow Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioNow Companies for you to search.

Showing News Articles 1–25 of 982 from BioNow

Thursday 21st September 2017

Manchester company Zilico help raise awareness of Gynae Cancer

A Manchester cervical cancer diagnostic company, is helping to raise awareness of the five gynaecological cancers - womb, ovarian, cervical, vaginal and vulval - in support of Gynaecological Cancer Awareness Month.Throughout September, Zilico, who are based on the Manchester Science Park, is supporting the UK campaign run by The Eve Appeal, to help more people become aware of the early signs and s...

High Force Research sets sights on North America

Leading North East-based chemical research and development company, High Force Research, is looking across the Atlantic as it sets its sights on growth.Founded nearly three decades ago, High Force Research is one of the UK’s longest trading and most successful independent chemical research and development companies. The company specialises in supporting the development, synthesis and scale u...

Monday 18th September 2017

Great Opportunities for Small and Medium Enterprises in Greater Manchester and Cheshire and Warrington

Working in partnership with the GM Business Growth Hub and the Innovation Agency (North West Coast AHSN), Greater Manchester Academic Health Science Network (GM AHSN) is helping Small and Medium Enterprises (SMEs) to do business with the NHS.With funding from the European Regional Development Fund (ERDF), GM AHSN will support SMEs across Greater Manchester and East Cheshire with innovative produc...

Tuesday 12th September 2017

Global firm Hitachi chooses Sci-Tech Daresbury to expand UK presence

Hitachi High-Technologies (Europe), part of Japan’s Hitachi Group,is taking laboratory space in the campus’s newest building, Techspace One to set up its UK demonstration laboratory facility for its electron microscopy division. An international leading–edge technology company has chosen Sci-Tech Daresbury as its scientific base in the UK.Hitachi High-Technologies (Europe) is par...

Thursday 7th September 2017

Investment Opportunity - 'Discover' more about Absynth

Absynth Biologics, a company set on addressing the healthcare challenges of life-threatening bacterial infections with its innovative vaccines is now in the 'discover' phase on the Capital Cell Platform (Capital Cell is a successful European life sciences funding platform recently launched in the UK).HIGHLIGHTSAbsynth antigens are truly novel and harness both antibody and T cell responses There ar...

Tuesday 22nd August 2017

Seqirus to Launch Adjuvanted Influenza Vaccine in the UK

The launch of FLUAD® in UK represents an exciting milestone for Seqirus.  As the only global vaccine company solely dedicated to influenza, Seqirus are proud to help meet the significant health need in the elderly population in the UK and to contribute to reducing the burden of influenza in national, regional and local healthcare settings. New influenza vaccine offers improved protection ...

Wednesday 16th August 2017

Biofortuna Closes £1.6M Funding Round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding – supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical tria...

Tuesday 15th August 2017

i4i Connect: funding for SMEs to accelerate medical technology development

Offering up to £150,000 over a 6-12 month period, i4i Connect will help SMEs get to the point of eligibility for a full i4i award or, down the line, follow on-funding. This will enable accelerated development of promising medical technologies, in line with recommendations from the Government’s Accelerated Access Review.Martin Hunt, NIHR i4i Programme Director said:“SMEs have...

Monday 14th August 2017

Scavenging Catty Chemicals are available from Strem Chemicals UK

Sold in collaboration with BASF metals scavenging agents (MSA’S) are alumina, carbon or silica-based air stable free flowing powders with proprietary surface coatings. These are suitable for the removal of precious and base metal species from organic, aqueous, protic and aprotic reaction mixtures with metal loading capacities up to 13 wt% (depending on metal and process conditions). MSA&rsqu...

Avian Reagent price reductions

We strive at APHA Scientific to offer you the best value to our customers. Which is why we have reduced the cost of our Avian Reagents, by 30%.Peter Cousins APHA Scientifics Business Development Manager said:“It is great news that we are able to pass on savings to make it even more affordable for customers. So, I’m thrilled to announce that we have lowered the price of our Avian Reagen...

Tuesday 8th August 2017

Funding competition - Digital health technology catalyst 2017 round 1

Description:Innovate UK is to invest up to £8 million in projects that develop new digital technology solutions to healthcare challenges.Feasibility projects must range in size from total project costs of £50,000 to £75,000 and you must complete your project within one year.Industrial research and experimental development projects must range in size from total project costs of &p...

Monday 7th August 2017

Funding competition - Biomedical catalyst 2017 round 3: early stage

The aim of this competition is to support the development of technologies and processes including: disease prevention and proactive management of health and chronic conditions earlier and better detection and diagnosis of disease, leading to better patient outcomes tailored treatments that either change the underlying disease or offer potential cures The biomedical catalyst has 4 types of fun...

Friday 4th August 2017

Open consultation: Financing growth in innovative firms

Patient capital supports small firms to grow into large, world-leading businesses. These firms increase productivity by introducing new ideas into markets. The UK provides a fertile ground for world-leading innovation, but a lack of effective supply of patient capital continues to hold some UK firms back from commercialising this innovation successfully.This consultation sets out the evidence arou...

Wednesday 2nd August 2017

Glythera appoints Dr Mike Owen as non-executive director

Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect.Mike brings over 15 years of experience in the development and commercialisation of biopharmaceuticals. He was previously Senior Vice President and global...

Tuesday 1st August 2017

Data and Informatics Solution for all Small-Medium Biotech Organisation

You're a small-medium biotech organisation, drowning in a sea of disorganised Excel spreadsheets in different formats, saved in different locations and unable to bring them together to benefit from the value they potentially harness..... and the problem is growing!Does this sound familiar? You're not alone. We hear this a lot at LabKey and we have a solution, we can help. LABKEY BIOLOGICS - Goog...

Tuesday 25th July 2017

Lords Science and Technology Committee: New inquiry – Life Sciences and the Industrial Strategy

The Government set out in its Industrial Strategy Green Paper its intention to create a new Life Sciences strategy to make the UK the best place in the world to invest in life sciences. To tackle challenges like cancer and dementia it is important that the UK has a strong life sciences sector. But the sector faces a number of challenges and opportunities, including Brexit and making innovative new...

LabKey Server 17.2 is RELEASED with new features and functions - check it out !

We are excited to announce the release of LabKey Server v17.2! This release includes valuable enhancements to platform features and performance improvements including: Automatic Linking of Assay Data to Referenced Files: Files referenced in assay data are now directly linked from the assay's grid view. Image files are rendered as thumbnails.Panorama Enhancements: New support for Skyline Calibratio...

Thursday 20th July 2017

Prominent biotech and healthcare entrepreneur Dr Stephen Parker joins Liverpool ChiroChem as Chairman

Liverpool ChiroChem (LCC), the specialist supplier of chiral small molecules that are used as building blocks, fragments, active pharmaceutical ingredients (API) and intermediates in small molecule drug discovery, is pleased to announce the appointment of Dr Stephen Parker as Non-executive Chairman of the company.The appointment of Dr Parker marks a new growth phase for the Liverpool University sp...

Tuesday 11th July 2017

The journey from clinical to commercial success for cell and gene therapies

Every moment counts when working with life-saving and industry changing treatments. Our white paper offers actionable insights for those ready to shape this new landscape. Authored by AmerisourceBergen’s multi disciplinary and market-leading experts, readers will learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in th...

Thursday 22nd June 2017

Former PM David Cameron joins Northern Businesses Showcasing UK Life Science

The world’s largest biotech gathering taking place in San Diego this week, the BIO Convention, has seen the North of England showcase its offer to more than 60 countries - and former Prime Minister David Cameron talk down fears over what Brexit will mean for the sector. Four of the seven sponsors of the Department for International Trade's UK stand at BIO come from the North; including the A...

Tuesday 20th June 2017

Shield Therapeutics Completes £12M Fundraising

Newcastle-based Shield Therapeutics has completed its £12m fundraising. The pharmaceutical firm yesterday revealed plans to raise the money through a co-ordinated exercise of existing warrants at an exercise price of 150p per share to raise approximately £10.3m, a placing of new ordinary shares at 150p per share to raise about £1.5m and a subscription of new ordinary shares at 1...

Manchester start-up creates world’s most powerful optical microscope

LIG Nanowise, based at Manchester Science Park, specialise in microscope technology aimed at the industrial, medical and research and development sectors.The NANOPSIS has super resolution microsphere amplified lens - which will allow scientists to see objects the size of a virus. The new technology combines traditional optical microscopy with tiny particles, called transparent microspheres, that ...

Thursday 15th June 2017

Cytox raises £2.6m led by Catapult Ventures to launch predictive test for Alzheimer’s Disease

Alderley Park, UK – 14 June 2017. Cytox, a leader in genetic testing for Alzheimer’s Disease, today announced that it has raised £2.6m to fund the commercial launch and international roll out of its novel service. The funding round was led by the GM&C Life Sciences Fund, managed by Catapult Ventures, alongside existing and new investors, including Perivoli Innovations, The Ra...

Monday 12th June 2017

Videregen joins UK's Social Stock Exchange

Videregen Limited, a clinical stage regenerative medicine company developing personalised organ replacements, is pleased to announce that it has become a member of the UK Social Stock Exchange (SSX), a platform which links up businesses and investors focused on impact investing. The SSX provides a significant new source of capital for Videregen as it develops and expands its replacement organ port...

Saturday 3rd June 2017

Carrier blocks using gold in biomedicine

This can be taken advantage of by a conjugation to biomolecules, enabled by the chemical affinity of gold to thiol groups: biomolecules such as peptides, oligonucleotides, or antibodies, can be attached to gold surfaces by using covalent thiol bonding with or without spacer molecules. In any case, the gold surface must be accessible to the molecules directly or by means of ligand exchange (replaci...


Quick Search
Advertisement
 

News Quicklinks